Capstone Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capstone Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.7M	Buy	+99,000	New	+$13.4M	0.03%	251
2026 Q1	–	Sell	-20,200	Closed	-$2.46M	–	1880
2025 Q4	$2.46M	Buy	+20,200	New	+$2.32M	﹤0.01%	551
2024 Q4	–	Sell	-75,000	Closed	-$7.41M	–	2038
2024 Q3	$7.41M	Buy	+75,000	New	+$7.37M	0.02%	364
2023 Q3	–	Sell	-30,000	Closed	-$2.5M	–	2314
2023 Q2	$2.5M	Buy	+30,000	New	+$2.51M	0.01%	577
2021 Q3	–	Sell	-76,000	Closed	-$10.3M	–	2079
2021 Q2	$10.3M	Buy	+76,000	New	+$9.99M	0.02%	527

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Capstone Investment Advisors's XBI Position: Q2 2026 in Review

Capstone Investment Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 30% in Q2 2026, selling an estimated $2.36M and leaving 40,463 shares worth $6.4M. The position accounts for 0.01% of the portfolio, ranked #449.

Capstone Investment Advisors first reported a position in XBI in Q2 2021 and has held it in 15 quarters since. The position peaked at $9.87M in Q4 2021. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Capstone Investment Advisors held 40,463 shares of State Street SPDR S&P Biotech ETF worth $6.4M as of Q2 2026.
Capstone Investment Advisors sold 17,452 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $2.36M.
State Street SPDR S&P Biotech ETF made up 0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #449 holding.
Capstone Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 15 quarters since.
Capstone Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $9.87M in Q4 2021.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.